If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ™ (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Does Omvoh™ (mirikizumab-mrkz) have any drug interactions with other medications?
Eli Lilly and Company has not sponsored any drug-drug interaction studies in patients with ulcerative colitis at the recommended induction or maintenance doses for Omvoh (mirikizumab).
Population pharmacokinetic analyses in patients with ulcerative colitis (UC) indicated that the clearance of mirikizumab was not impacted by concomitant administration of
- aminosalicylates (5-ASAs)
- corticosteroids, or
- oral immunomodulators, such as 6-mercaptopurine (6-MP), azathioprine (AZA), methotrexate (MTX), and tioguanine.1
Based on a clinical drug-drug interaction study conducted in patients with another condition, multiple subcutaneous (SC) doses of mirikizumab-mrkz 250 mg every 4 weeks (a dosage 1.25-times higher than the recommended maintenance dosage) did not result in changes in the exposure of midazolam (CYP3A substrate), warfarin (CYP2C9 substrate), dextromethorphan (CYP2D6 substrate), omeprazole (CYP2C19 substrate), or caffeine (CYP1A2 substrate).1
Enclosed Prescribing Information
1Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: May 30, 2023